Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHW289)

Drug Name
DCC-3014 Drug Info
Synonyms
Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Haematological malignancy 2B33.Y Phase 1 [2]
Cross-matching ID
PubChem CID
86267612
CAS Number
CAS 1628606-05-2
TTD Drug ID
DMHW289

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [3]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [2]
ARRY-382 DM0VGDC Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
BLZ-945 DMG1LVA Amyotrophic lateral sclerosis 8B60.0 Phase 2 [2]
Cabiralizumab DMGE058 Pancreatic cancer 2C10 Phase 2 [4]
AMB-05X DM958C5 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [5]
FPA-008 DM3ZN6Y Autoimmune diabetes 5A10 Phase 1/2 [6]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [2]
TPX-0022 DMC2IJN Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
SNDX-6352 DM8ZROW Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [3]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [2]
ARRY-382 DM0VGDC Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
BLZ-945 DMG1LVA Amyotrophic lateral sclerosis 8B60.0 Phase 2 [2]
Cabiralizumab DMGE058 Pancreatic cancer 2C10 Phase 2 [4]
AMB-05X DM958C5 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [5]
FPA-008 DM3ZN6Y Autoimmune diabetes 5A10 Phase 1/2 [6]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [2]
TPX-0022 DMC2IJN Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
SNDX-6352 DM8ZROW Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Macrophage colony-stimulating factor 1 receptor (CSF1R) TT7MRDV CSF1R_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03069469) Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of AmMax Bio
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of Turning Point Therapeutics.